Elanco Animal Health Incorporated Intangible Assets, Net (Excluding Goodwill)
Elanco Animal Health Incorporated (ELAN) had Intangible Assets, Net (Excluding Goodwill) of $3.20 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-05
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $3.20B.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $3.23B.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $3.41B.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $3.60B.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $3.20B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $3.23B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $3.41B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $3.60B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $3.71B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $3.63B 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $3.68B 10-K · filed 2026-02-24 | |
| 2024-09-30 | $4.01B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $4.00B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $4.20B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $4.49B 10-K · filed 2025-02-25 | |
| 2023-09-30 | $4.47B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $4.68B 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $4.79B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $4.84B 10-K · filed 2024-02-26 | |
| 2022-09-30 | $4.77B 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $5.06B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $5.39B 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $5.59B 10-K · filed 2023-03-01 | |
| 2021-09-30 | $5.82B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $5.75B 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $6.03B 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $6.39B 10-K · filed 2022-02-28 | $6.39B 10-K · filed 2021-03-01 |
| 2020-09-30 | $5.79B 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $2.43B 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $2.46B 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.48B 10-K · filed 2021-03-01 | |
| 2019-09-30 | $2.44B 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $2.35B 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $2.39B 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $2.50B 10-K · filed 2020-02-28 | $2.45B 10-K · filed 2019-02-20 |
| 2018-09-30 | $2.51B 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $2.67B 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |